ID: ALA2011750

Max Phase: Preclinical

Molecular Formula: C22H20I2N4O2

Molecular Weight: 626.24

Molecule Type: Small molecule

Representations

Canonical SMILES:  N=C(N)c1ccc(OCc2ccc(COc3ccc(C(=N)N)cc3I)cc2)c(I)c1

Standard InChI:  InChI=1S/C22H20I2N4O2/c23-17-9-15(21(25)26)5-7-19(17)29-11-13-1-2-14(4-3-13)12-30-20-8-6-16(22(27)28)10-18(20)24/h1-10H,11-12H2,(H3,25,26)(H3,27,28)

Standard InChI Key:  YGBZFHXWPPQSHR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 626.24

Molecular Weight (Monoisotopic): 625.9676

AlogP: 4.62

#Rotatable Bonds: 8

Polar Surface Area: 118.20

Molecular Species: BASE

HBA: 4

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 11.82

CX LogP: 4.81

CX LogD: -0.01

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.17

Np Likeness Score: -0.33

References

1. Liang G, Chen X, Aldous S, Pu SF, Mehdi S, Powers E, Xia T, Wang R..  (2012)  Human kallikrein 6 inhibitors with a para-amidobenzylanmine P1 group identified through virtual screening.,  22  (7): [PMID:22386244] [10.1016/j.bmcl.2012.02.014]

2. Parrish RF, Straus JW, Paulson JD, Polakoski KL, Tidwell RR, Geratz JD, Stevens FM..  (1978)  Structure-activity relationships for the inhibition of acrosin by benzamidine derivatives.,  21  (11): [PMID:722718] [10.1021/jm00209a008]

Source

Source(1):

• Scientific Literature